Satisfying needs for
niche Specialty Care products
00 / pharma& news
30/07/2021
pharma& Enters into a Strategic Partnership with Heritage Biologics Aimed at Improving Patient Access and Care
Vienna, Austria and Kansas City, Missouri, USA on 30 July 2021.
zr pharma& GmbH (“pharma&”) today announced that its wholly-owned subsidiary, pharma& U.S. Inc., has entered into an agreement with Heritage Biologics, LLC (“Heritage Biologics”) acquiring 50% of the company’s shares.
Heritage Biologics and pharma& (advised by E3 Life) emphasized the strategic nature of the transaction, which offers substantial growth opportunities as well as synergies in securing access and improving clinical outcomes for patients with complex, often chronic, and rare conditions.
Tom O’Neill, owner and CEO of Heritage Biologics stated: “We look forward to fully leveraging pharma&’s network, its product acquisition pipeline, and access to capital to execute on Heritage Biologics’ ambitious growth plans.”
Elmar Zagler and Frank Rotmann, co-owners and officers of pharma& mentioned: “After intense scouting we are thrilled to have found in Heritage Biologics a US partner offering a strong foothold for our existing business together with significant upside potential in creating value for our stakeholders and patients alike”
About Heritage Biologics:
Heritage Biologics is a home-infusion specialty pharmacy that specializes in the treatment of rare and chronic diseases. Our founders, unsatisfied with their own experiences and failures as rare-disease patients, understood that the only way to achieve higher outcomes and a better quality of life is through patient-centric care. Our team developed the world’s first pharmacy patient experience program, and from there, Heritage was born. From creating our own patient portal and data platform that provides care teams with real-time health analytics, to augmented reality devices that can help ensure better venous access, we have implemented tools that have engraved our legacy as pioneers in value based healthcare. For more information, please visit www.heritagebiologics.com.
01 / pharma& is
pharma& is a privately owned company, aiming at satisfying needs for niche, original, Specialty Care products.
Our commitment to patient access for well-established original Specialty Care medicines and our worldwide presence of own subsidiaries, affiliated companies and partnerships, secure sustainable product availibilty in markets around the world.
02 / pharma& story
After having acquired multiple products in various therapeutic areas and having established a profound base to secure patient access and to supply products across the entire European Landscape we have expanded our footprint to serve patients around the world.
We are proud of our “every patient counts” commitment and our strong partnership network.
03 / pharma& team
All of us have been trained over decades in Top Tier Global Pharmaceutical Companies, coming together as a team, committed and enjoying to grow together.
Supported by our trusted network of highly qualified service providers and experts, we want to shape our future and to leave footprints for the benefits of our patients, their caregivers and our stakeholders.
04 / pharma& founders
Frank Rotmann
" Throughout my 20+ years
in the industry, I have developed a track record in building
and developing organisations
for growth! "
Elmar Zagler
" Having started my career in Finance, I know how to optimize businesses and
how to leverage
networks & alliances! "
05 / pharma& portfolio
05.1 / prescription medicines
05.2 / consumer health
05.3 / affiliated companies
06 / pharma& pharmacovigilance contact
IN GERMAN
Bei Nebenwirkungen wenden Sie sich bitte an
oder schreiben Sie ein Email an pv@drehm.at.
Zusätzlich können Sie auch direkt über die Homepage des Bundesamtes für Sicherheit im Gesundheitswesen (http://www.basg.gv.at) Nebenwirkungsfälle melden.
IN ENGLISH
In case of adverse events, please contact
or send an Email to pv@drehm.at.
Additionally, you can also report adverse events via your local health authorities.
IN DUTCH
Voor het melden van bijwerkingen, contacteer
of u kunt een e-mail sturen naar pharmacovigilance@bfc.nl.
Daarnaast kunt u bijwerkingen ook melden bij het Lareb, www.lareb.nl.